Your browser doesn't support javascript.
loading
Study on anti-inflammatory effect of peptides-conjugated alumina nanoparticle on allergic rhinitis mice model.
Li, Li; Wang, Jing; Athari, Seyyed Shamsadin; Jiang, Chao-Wu.
Affiliation
  • Li L; Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China.
  • Wang J; Department of Otorhinolaryngological, Dezhou Second People's Hospital, Dezhou, China.
  • Athari SS; Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Jiang CW; Department of Otolaryngology Division I, The First Affiliated Hospital of Kunming Medical University, Kunming, China; alex.md313@gmail.com; jcw15812082830@outlook.com.
Allergol Immunopathol (Madr) ; 51(3): 111-116, 2023.
Article in En | MEDLINE | ID: mdl-37169568
ABSTRACT
Allergic rhinitis (AR) is a common atopic problem in which immune response to the environmental factors leads to clinical symptoms. Helicobacter pylori neutrophil-activating protein (HP-NAP) as a peptide attenuates Th2 response and stimulates Th1 activation and mucus adhesion promoting protein (MapA) as a cell-surface protein binds to mucus. This study evaluated the effect of HP-NAP and MapA conjugated with alumina nanoparticle on AR. HP-NAP and HP-NAP with MapA were conjugated to alumina nanoparticle and two separate nanoparticles were produced. The AR mice were treated with these and HP-NAP in peptide form. The AR symptoms, gene expression of mucus, levels of IL-33 and IL-4, and total and ovalbumin (OVA)-specific IgE levels were evaluated. Nasal rubbing, sneezing, gene expression of mucus, and IL-33 and IL-4 levels, and OVA-specific and total IgE were decreased in three treated groups compared to AR, and there was a significant decrease in the symptoms in AR-H-M-A group (P < 0.05) when compared to the other treated groups. HP-NAP has a controlling effect on AR, and in nanoparticle-conjugated form it can strongly attach to the airway's mucus via MapA. Therefore, cooperation of HP-NAP-alumina with MapA can produce an effective and applicable treatment for AR.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhinitis, Allergic / Interleukin-33 Type of study: Prognostic_studies Limits: Animals Language: En Journal: Allergol Immunopathol (Madr) Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhinitis, Allergic / Interleukin-33 Type of study: Prognostic_studies Limits: Animals Language: En Journal: Allergol Immunopathol (Madr) Year: 2023 Document type: Article Affiliation country: China